Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 705 - 720 of 91813 for .

Showing results 705 - 720 of 91813 for .

Covance MarketPlace - BioWorld's Partner in Focus
BioWorld's Partner in Focus - Covance MarketPlace
How to Maximize Patient Recruitment in Oncology Trials
Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of drug development programs. This article highlights unique expertise, tools and other attributes that can help companies excel in oncology clinical trials.
"Fail Fast" Using Toxicology Endpoints in Pharmacology Studies
This article focuses on how biopharmaceutical companies that employ a "fail fast" strategy can make safety decisions from the integration of toxicology into pharmacology studies, which markedly reduces lead optimization cycle times and overall spend during this phase.
Health Economics: Too important to be left to health economists?
Is the role of the health economist an academid and scientific one or is their job essentially to support product sales as an extension of the commercial and marketing departments?
COVANCE CENTRAL LABORATORY SERVICES COMPLETES ISO 15189:2012 ACCREDITATION
As a continued commitment to meet sponsors' needs and extend ongoing quality, Covance recently completed ISO 15189:2012 accreditation at the Indianapolis laboratory, the largest central laboratory in the United States. The US site joins locations in Switzerland, Singapore, China and Japan that have achieved this milestone.
Market Access Insight: Commercial Considerations
Discover the importance of developing and executing on a market access strategy early to optimize the commercial success of a product.
Stepping Up the Game: Measles, Mumps, Rubella and Varicella (MMRV) Concomitant Testing Support for Vaccine Evaluation
Vaccines against Measles, Mumps, Rubella (MMR), and Varicella (the "V" in MMRV vaccines) are a core component in most pediatric immunization programs across the world. Hence, every time a new pediatric vaccine is added to the existing immunization schedule, clinical evidence must be provided that the newcomer does not adversely influence the immunogenic response to the MMRV-licensed vaccines. As more vaccines are introduced and the number of analyses required to pass FDA review increases,...
Reducing the Variability in Multiple Myeloma Testing
This four-page article discusses our approach to reducing the variability in Multiple Myeloma testing and how we provide globally combinable data and high-quality results.
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway
The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing world-wide in parallel to the increase of the obesity epidemic. Insulin resistance (IR) and the accumulation of triglyceride-derived toxic lipid metabolites play a key role in its pathogenesis. Multiple biomarkers are being evaluated for the non-invasive diagnosis of NASH.
NASH: How To Conquer This Global Health Crisis
5 Challenges and Best Practices of NASH Clinical Research.
Understanding the Power of Natural Killer Cells and New Non-Radioactive Assay Approaches
Natural killer (NK) cells first earned their title as "killers" nearly 40 years ago when researchers observed the rapid immune response of these lymphocytes as they destroyed host cells infected with a virus or tumor cells. Today, the NK cell assay is used to support specialty immunotoxicology studies for safety assessment. At Covance, we work with clients that often ask us about performing a NK cell functional analysis and the role of standard immunophenotyping to enumerate cells. This...
SMPRs Approved for High-Priority Dietary Supplements: Phosphodiesterase Type 5 Inhibitors
Reprint from AOAC INTERNATIONAL's Inside Laboratory Management
Pediatric clinical trials: Navigating evolving regulations successfully with the right partner
Gone are the days when pediatric patients were considered simply as miniature adults. Drug developers and regulators alike agree that younger patients, with their developing bodies, are bound to respond differently to pharmaceutical products. To ensure that this younger cohort receives safe and effective treatment, regulations governing clinical trials are evolving, creating new challenges for drug developers. Working with the right partner can help you navigate the road ahead.
Protect Consumers - A Case for Pesticide Residues Analysis
Protect Consumers - A Case for Pesticide Residues Analysis
TQT Waivers: One Year Later - Overcoming Design Challenges
It has been one year since the International Conference on Harmonisation (ICH) updated its 2005 cardiac safety guidelines. The 2015 update allows for specific QT interval analysis based upon concentration effect modeling up to supratherapeutic during Phase I as a reasonable substitute for a Thorough-QT (TQT) dedicated trial. These Phase I data along with preclinical results are submitted to the FDA prior to Phase III as a waiver request from a separate TQT study. This is good news! A...
INNOVATION IS UNDERWAY: INTRODUCING VACCINE AND NOVEL IMMUNOTHERAPEUTIC CLINICAL LABORATORY SOLUTIONS
In an effort to fully support the industry's advances in vaccines and novel immunotherapeutics, Covance has formed a unique, cross-functional team of scientific and operational experts. This group offers a strategic relationship to uncover greater efficiencies and accelerate a product's journey to its next milestone.